Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INB 03

Drug Profile

INB 03

Alternative Names: INB-03; XPro-1595

Latest Information Update: 16 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Emory University; Xencor
  • Developer Alzheimer's Association; Emory University; FPRT Bio; INmune Bio; Xencor
  • Class Anti-inflammatories; Antidementias; Antineoplastics; Antiparkinsonians; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Immunostimulants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease; Solid tumours
  • No development reported Neurodegenerative disorders; Parkinson's disease

Most Recent Events

  • 12 Sep 2019 INmune Bio receives patent allowance for INB 03 in USA
  • 04 Sep 2019 INmune Bio completes a phase I trial in Solid tumours in Australia (ACTRN12618000675224)
  • 05 Aug 2019 Pharmacokinetics, pharmacodynamics and adverse event data from a phase I trial in indication presented at the 7th Annual Immuno-Oncology Summit-2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top